He joined CIL in 1996, became Partner in 2003 and head of Healthcare in 2005. He ran the practice until he stepped back to senior advisor and non-executive director in 2022.
He was also Managing Partner 2019-22. He has led numerous engagements across a range of life sciences, health tech, products and services markets. Giles has particular experience conducting sell- and buy-side commercial due diligence for private equity investors in the sector such as GHO, Apposite Capital, Archimed, Elysian Capital and CBPE.
